Biomarkers for prognosis in pancreatic neuroendocrine tumors

in Endocrine-Related Cancer
Authors:
Mojun Zhu Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA

Search for other papers by Mojun Zhu in
Current site
Google Scholar
PubMed
Close
,
Karl R Sorenson Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA

Search for other papers by Karl R Sorenson in
Current site
Google Scholar
PubMed
Close
,
Rebecca Liu Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA

Search for other papers by Rebecca Liu in
Current site
Google Scholar
PubMed
Close
,
Bonnie E Gould Rothberg Smilow Cancer Hospital, Yale-New Haven Health System, New Haven, Connecticut, USA

Search for other papers by Bonnie E Gould Rothberg in
Current site
Google Scholar
PubMed
Close
, and
Thorvardur R Halfdanarson Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA

Search for other papers by Thorvardur R Halfdanarson in
Current site
Google Scholar
PubMed
Close

Correspondence should be addressed to M Zhu: zhu.mojun@mayo.edu
Restricted access
Rent on DeepDyve

Sign up for journal news

Pancreatic neuroendocrine tumors (PNETs) encompass a diverse group of malignancies marked by histological heterogeneity and highly variable clinical outcomes. We performed a systematic review on potential prognostic biomarkers in PNETs by searching the PubMed database. A total of 472 manuscripts were reviewed in detail, of which 52 multivariate studies met the inclusion criteria proposed by the Reporting Recommendations for Tumor Marker Prognostic Studies. These altogether analyzed 53 unique targets, and 36 of them were statistically associated with survival.

Supplementary Materials

    • Supplementary Table 1. Multivariate studies included in this study

 

  • Collapse
  • Expand
  • Alexakis N, Connor S, Ghaneh P, Lombard M, Smart HL, Evans J, Hughes M, Garvey CJ, Vora J & Vinjamuri S et al.2004 Hereditary pancreatic endocrine tumours. Pancreatology 4 417433; discussion 434415. (https://doi.org/10.1159/000079616)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW & Terstappen LW 2004 Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clinical Cancer Research 10 68976904. (https://doi.org/10.1158/1078-0432.CCR-04-0378)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Al-Toubah T, Cives M, Valone T, Blue K & Strosberg JR 2020 Sensitivity and specificity of the NETest: a validation study. Neuroendocrinology 111 580585. (https://doi.org/10.1159/000509866)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Bodei L, Kidd M, Modlin IM, Severi S, Drozdov I, Nicolini S, Kwekkeboom DJ, Krenning EP, Baum RP & Paganelli G 2016 Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. European Journal of Nuclear Medicine and Molecular Imaging 43 839851. (https://doi.org/10.1007/s00259-015-3250-z)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Bodei L, Kidd MS, Singh A, van der Zwan WA, Severi S, Drozdov IA, Cwikla J, Baum RP, Kwekkeboom DJ & Paganelli G et al.2018 PRRT genomic signature in blood for prediction of (177)Lu-octreotate efficacy. European Journal of Nuclear Medicine and Molecular Imaging 45 11551169. (https://doi.org/10.1007/s00259-018-3967-6)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Bodei L, Kidd MS, Singh A, van der Zwan WA, Severi S, Drozdov IA, Malczewska A, Baum RP, Kwekkeboom DJ & Paganelli G et al.2020 PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest. European Journal of Nuclear Medicine and Molecular Imaging 47 895906. (https://doi.org/10.1007/s00259-019-04601-3)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Cai L, Michelakos T, Deshpande V, Arora KS, Yamada T, Ting DT, Taylor MS, Castillo CF, Warshaw AL & Lillemoe KD et al.2019 Role of tumor-associated macrophages in the clinical course of pancreatic neuroendocrine tumors (PanNETs). Clinical Cancer Research 25 26442655. (https://doi.org/10.1158/1078-0432.CCR-18-1401)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Cejas P, Drier Y, Dreijerink KMA, Brosens LAA, Deshpande V, Epstein CB, Conemans EB, Morsink FHM, Graham MK & Valk GD et al.2019 Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors. Nature Medicine 25 12601265. (https://doi.org/10.1038/s41591-019-0493-4)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Cesare AJ & Reddel RR 2010 Alternative lengthening of telomeres: models, mechanisms and implications. Nature Reviews: Genetics 11 319330. (https://doi.org/10.1038/nrg2763)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Chan DL, Clarke SJ, Diakos CI, Roach PJ, Bailey DL, Singh S & Pavlakis N 2017 Prognostic and predictive biomarkers in neuroendocrine tumours. Critical Reviews in Oncology/Hematology 113 268282. (https://doi.org/10.1016/j.critrevonc.2017.03.017)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Chan CS, Laddha SV, Lewis PW, Koletsky MS, Robzyk K, Da Silva E, Torres PJ, Untch BR, Li J & Bose P et al.2018 ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup. Nature Communications 9 4158. (https://doi.org/10.1038/s41467-018-06498-2)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Cives M, Partelli S, Palmirotta R, Lovero D, Mandriani B, Quaresmini D, Pelle E, Andreasi V, Castelli P & Strosberg J et al.2019 DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors. Scientific Reports 9 18614. (https://doi.org/10.1038/s41598-019-55156-0)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E & Miller MC et al.2008 Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. Journal of Clinical Oncology 26 32133221. (https://doi.org/10.1200/JCO.2007.15.8923)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ & Terstappen LW et al.2004 Circulating tumor cells, disease progression, and survival in metastatic breast cancer. New England Journal of Medicine 351 781791. (https://doi.org/10.1056/NEJMoa040766)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Ćwikła JB, Bodei L, Kolasinska-Ćwikła A, Sankowski A, Modlin IM & Kidd M 2015 Circulating transcript analysis (NETest) in GEP-NETs treated with somatostatin analogs defines therapy. Journal of Clinical Endocrinology and Metabolism 100 E1437E1445. (https://doi.org/10.1210/jc.2015-2792)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ & Raghavan D 2008 Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clinical Cancer Research 14 63026309. (https://doi.org/10.1158/1078-0432.CCR-08-0872)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • de Reuver PR, Mehta S, Gill P, Andrici J, D'Urso L, Clarkson A, Mittal A, Hugh TJ, Samra JS & Gill AJ 2016 Immunoregulatory forkhead box protein p3-positive lymphocytes are associated with overall survival in patients with pancreatic neuroendocrine tumors. Journal of the American College of Surgeons 222 281287. (https://doi.org/10.1016/j.jamcollsurg.2015.12.008)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Drane P, Ouararhni K, Depaux A, Shuaib M & Hamiche A 2010 The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3. Genes and Development 24 12531265. (https://doi.org/10.1101/gad.566910)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Ehehalt F, Saeger HD, Schmidt CM & Grutzmann R 2009 Neuroendocrine tumors of the pancreas. Oncologist 14 456467. (https://doi.org/10.1634/theoncologist.2008-0259)

  • Ekeblad S, Lejonklou MH, Stalberg P & Skogseid B 2012 Prognostic relevance of survivin in pancreatic endocrine tumors. World Journal of Surgery 36 14111418. (https://doi.org/10.1007/s00268-011-1345-7)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, Kos-Kudla B, Kwekkeboom D, Rindi G & Kloppel G et al.2016 ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology 103 153171. (https://doi.org/10.1159/000443171)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Fendrich V, Waldmann J, Bartsch DK & Langer P 2009 Surgical management of pancreatic endocrine tumors. Nature Reviews: Clinical Oncology 6 419428. (https://doi.org/10.1038/nrclinonc.2009.82)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Gabrilovich DI & Nagaraj S 2009 Myeloid-derived suppressor cells as regulators of the immune system. Nature Reviews: Immunology 9 162174. (https://doi.org/10.1038/nri2506)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Gaitanidis A, Patel D, Nilubol N, Tirosh A, Sadowski S & Kebebew E 2018 Markers of systemic inflammatory response are prognostic factors in patients with pancreatic neuroendocrine tumors (PNETs): a prospective analysis. Annals of Surgical Oncology 25 122130. (https://doi.org/10.1245/s10434-017-6241-4)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Gamboa AC, Ethun CG, Postlewait LM, Lopez-Aguiar AG, Zhelnin K, Krasinskas A, El-Rayes BF, Russell MC, Kooby DA & Staley CA et al.2020 HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: potential for a novel therapeutic target. Surgical Oncology 35 460465. (https://doi.org/10.1016/j.suronc.2020.09.018)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Genç CG, Jilesen APJ, Nieveen van Dijkum EJM, Klümpen HJ, van Eijck CHJ, Drozdov I, Malczewska A, Kidd M & Modlin I 2018 Measurement of circulating transcript levels (NETest) to detect disease recurrence and improve follow-up after curative surgical resection of well-differentiated pancreatic neuroendocrine tumors. Journal of Surgical Oncology 118 3748.(https://doi.org/10.1002/jso.25129)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Genc CG, Klumpen HJ, van Oijen MGH, van Eijck CHJ & Nieveen van Dijkum EJM 2018 A nationwide population-based study on the survival of patients with pancreatic neuroendocrine tumors in the Netherlands. World Journal of Surgery 42 490497. (https://doi.org/10.1007/s00268-017-4278-y)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Goldberg AD, Banaszynski LA, Noh KM, Lewis PW, Elsaesser SJ, Stadler S, Dewell S, Law M, Guo X & Li X et al.2010 Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell 140 678691. (https://doi.org/10.1016/j.cell.2010.01.003)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Halfdanarson TR, Rabe KG, Rubin J & Petersen GM 2008 Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Annals of Oncology 19 17271733. (https://doi.org/10.1093/annonc/mdn351)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, OʼDorisio TM, Halperin DM, Fishbein L, Eads J & Hope TA et al.2020 The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of pancreatic neuroendocrine tumors. Pancreas 49 863881.(https://doi.org/10.1097/MPA.0000000000001597)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Han X, Zhang C, Tang M, Xu X, Liu L, Ji Y, Pan B & Lou W 2015 The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases. European Journal of Gastroenterology and Hepatology 27 527535. (https://doi.org/10.1097/MEG.0000000000000332)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Harimoto N, Hoshino K, Muranushi R, Hagiwara K, Yamanaka T, Ishii N, Tsukagoshi M, Igarashi T, Tanaka H & Watanabe A et al.2019 Prognostic significance of neutrophil-lymphocyte ratio in resectable pancreatic neuroendocrine tumors with special reference to tumor-associated macrophages. Pancreatology 19 897902. (https://doi.org/10.1016/j.pan.2019.08.003)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Howe JR, Merchant NB, Conrad C, Keutgen XM, Hallet J, Drebin JA, Minter RM, Lairmore TC, Tseng JF & Zeh HJ et al.2020 The North American Neuroendocrine Tumor Society consensus paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas 49 133. (https://doi.org/10.1097/MPA.0000000000001454)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Hua J, Shi S, Xu J, Wei M, Zhang Y, Liu J, Zhang B & Yu X 2020 Expression patterns and prognostic value of DNA damage repair proteins in resected pancreatic neuroendocrine neoplasms. Annals of Surgery [epub]. (https://doi.org/10.1097/SLA.0000000000003884)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Inzani F, Petrone G & Rindi G 2018 The New World Health Organization classification for pancreatic neuroendocrine neoplasia. Endocrinology and Metabolism Clinics of North America 47 463470. (https://doi.org/10.1016/j.ecl.2018.04.008)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL & Choti MA et al.2011 DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331 11991203. (https://doi.org/10.1126/science.1200609)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Jimenez-Fonseca P, Krug S, Tamagno G, Fierro Maya F, Monleon Getino A, Rodriguez Casado CI, Costa F, de Herder WW & Jann H 2018a Identifying prognostic factors for well-differentiated metastatic pancreatic neuroendocrine tumours: a retrospective international multicentre cohort study. Neuroendocrinology 107 315323. (https://doi.org/10.1159/000492223)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Jimenez-Fonseca P, Martin MN, Carmona-Bayonas A, Calvo A, Fernandez-Mateos J, Redrado M, Capdevila J, Lago NM, Lacasta A & Munarriz J et al.2018b Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib. Oncotarget 9 3689436905. (https://doi.org/10.18632/oncotarget.26380)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Kidd M, Bodei L, Drozdov I, Kwekkeboom D, Krenning E, Baum R, Frilling A, Cwikla J, Prasad V & Modlin I 2016 Circulating neuroendocrine gene transcripts – the NETest – accurately identify GEP-NETs, are decreased by surgery and predict tumor progression and recurrence. In NANETS 2016 Conference Abstracts abstract AB02. (available at: https://nanets.net/abstracts-archive/2016/412-ab2-circulating-neuroendocrine-gene-transcripts-a-the-netest-a-accurately-identify-gep-nets-are-decreased-by-surgery-and-predict-tumor-progression-and-recurrence/file)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Kidd M, Kitz A, Drozdov IA & Modlin IM 2020 Neuroendocrine tumor omic gene cluster analysis amplifies the prognostic accuracy of the NETest. Neuroendocrinology 111 490504. (https://doi.org/10.1159/000508573)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Kim JY, Brosnan-Cashman JA, An S, Kim SJ, Song KB, Kim MS, Kim MJ, Hwang DW, Meeker AK & Yu E et al.2017 Alternative lengthening of telomeres in primary pancreatic neuroendocrine tumors is associated with aggressive clinical behavior and poor survival. Clinical Cancer Research 23 15981606. (https://doi.org/10.1158/1078-0432.CCR-16-1147)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Kim C, Jeong DE, Heo S, Ji E, Rho JG, Jung M, Ahn S, Kim YJ, Kim YS & Nam SW et al.2018 Reduced expression of the RNA-binding protein HuD in pancreatic neuroendocrine tumors correlates with low p27(Kip1) levels and poor prognosis. Journal of Pathology 246 231243. (https://doi.org/10.1002/path.5135)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Klieser E, Urbas R, Stattner S, Primavesi F, Jager T, Dinnewitzer A, Mayr C, Kiesslich T, Holzmann K & Di Fazio P et al.2017 Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors: HDAC5 as a predictor of poor clinical outcome. Human Pathology 65 4152. (https://doi.org/10.1016/j.humpath.2017.02.009)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Kunz PL, Catalano PJ, Nimeiri H, Fisher GA, Longacre TA, Suarez CJ, Yao JC, Kulke MH, Hendifar AE & Shanks JC et al.2018 A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: a trial of the ECOG-ACRIN Cancer Research Group (E2211). Journal of Clinical Oncology 36 40044004. (https://doi.org/10.1200/JCO.2018.36.15_suppl.4004)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Lee HS, Chen M, Kim JH, Kim WH, Ahn S, Maeng K, Allegra CJ, Kaye FJ, Hochwald SN & Zajac-Kaye M 2014 Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival. International Journal of Cancer 135 128137. (https://doi.org/10.1002/ijc.28675)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Lewis PW, Elsaesser SJ, Noh KM, Stadler SC & Allis CD 2010 Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. PNAS 107 1407514080. (https://doi.org/10.1073/pnas.1008850107)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Liu B, Tang LH, Liu Z, Mei M, Yu R, Dhall D, Qiao XW, Zhang TP, Zhao YP & Liu TH et al.2014 Alpha-internexin: a novel biomarker for pancreatic neuroendocrine tumor aggressiveness. Journal of Clinical Endocrinology and Metabolism 99 E786E795. (https://doi.org/10.1210/jc.2013-2874)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Liu B, Kudo A, Kinowaki Y, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Tanaka S & Akashi T et al.2019a A simple and practical index predicting the prognoses of the patients with well-differentiated pancreatic neuroendocrine neoplasms. Journal of Gastroenterology 54 819828. (https://doi.org/10.1007/s00535-019-01570-0)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Liu E, Paulson S, Gulati A, Freudman J, Grosh W, Kafer S, Wickremesinghe PC, Salem RR & Bodei L 2019b Assessment of NETest clinical utility in a U.S. Registry-based study. Oncologist 24 783790. (https://doi.org/10.1634/theoncologist.2017-0623)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Lloyd RV, Or KG & Rosai J 2017 WHO Classification of Tumours of Endocrine Organs. Lyon, France: International Agency for Research on Cancer. (available at: https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-Endocrine-Organs-2017)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Mandair D, Khan MS, Lopes A, Furtado O’Mahony L, Ensell L, Lowe H, Hartley JA, Toumpanakis C, Caplin M & Meyer T 2020 Prognostic threshold for circulating tumour cells in patients with pancreatic and midgut neuroendocrine tumours. Journal of Clinical Endocrinology and Metabolism 106 872882.(https://doi.org/10.1210/clinem/dgaa822)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Marinoni I, Kurrer AS, Vassella E, Dettmer M, Rudolph T, Banz V, Hunger F, Pasquinelli S, Speel EJ & Perren A 2014 Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology 146 453 .e546 0.e5. (https://doi.org/10.1053/j.gastro.2013.10.020)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Massironi S, Sciola V, Peracchi M, Ciafardini C, Spampatti MP & Conte D 2008 Neuroendocrine tumors of the gastro-entero-pancreatic system. World Journal of Gastroenterology 14 53775384. (https://doi.org/10.3748/wjg.14.5377)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • McKenna LR & Edil BH 2014 Update on pancreatic neuroendocrine tumors. Gland Surgery 3 258275. (https://doi.org/10.3978/j.issn.2227-684X.2014.06.03)

  • McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM & Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics 2005 Reporting recommendations for tumor marker prognostic studies (Remark). Journal of the National Cancer Institute 97 11801184. (https://doi.org/10.1093/jnci/dji237)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Milione M, Maisonneuve P, Spada F, Pellegrinelli A, Spaggiari P, Albarello L, Pisa E, Barberis M, Vanoli A & Buzzoni R et al.2017 The clinicopathologic heterogeneity of grade 3 gastroenteropancreatic neuroendocrine neoplasms: morphological differentiation and proliferation identify different prognostic categories. Neuroendocrinology 104 8593. (https://doi.org/10.1159/000445165)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Modlin IM, Drozdov I & Kidd MS 2013 A multitranscript blood neuroendocrine tumor molecular signature to identify treatment efficacy and disease progress. Journal of Clinical Oncology 31 41374137. (https://doi.org/10.1200/jco.2013.31.15_suppl.4137)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Modlin IM, Drozdov I, Alaimo D, Callahan S, Teixiera N, Bodei L & Kidd M 2014 A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection. Endocrine-Related Cancer 21 615628. (https://doi.org/10.1530/ERC-14-0190)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Modlin IM, Kidd M, Bodei L, Drozdov I & Aslanian H 2015 The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract. American Journal of Gastroenterology 110 12231232. (https://doi.org/10.1038/ajg.2015.160)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington KM, Carneiro F, Cree IA & WHO Classification of Tumours Editorial Board 2020 The 2019 WHO classification of tumours of the digestive system. Histopathology 76 182188. (https://doi.org/10.1111/his.13975)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Nanno Y, Toyama H, Zen Y, Akita M, Ando Y, Mizumoto T, Ueda Y, Ajiki T, Okano K & Suzuki Y et al.2018 Serum elastase 1 level as a risk factor for postoperative recurrence in patients with well-differentiated pancreatic neuroendocrine neoplasms. Annals of Surgical Oncology 25 33583364. (https://doi.org/10.1245/s10434-018-6675-3)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Oberg K & Eriksson B 2005 Endocrine tumours of the pancreas. Best Practice and Research: Clinical Gastroenterology 19 753781. (https://doi.org/10.1016/j.bpg.2005.06.002)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Öberg K, Califano A, Strosberg JR, Ma S, Pape U, Bodei L, Kaltsas G, Toumpanakis C, Goldenring JR & Frilling A et al.2020 A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood. Annals of Oncology 31 202212. (https://doi.org/10.1016/j.annonc.2019.11.003)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Oberstein PE & Saif MW 2012 Update on prognostic and predictive biomarkers for pancreatic neuroendocrine tumors. JOP 13 368371. (https://doi.org/10.6092/1590-8577/965)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Panni RZ, Lopez-Aguiar AG, Liu J, Poultsides GA, Rocha FG, Hawkins WG, Strasberg SM, Trikalinos NA, Maithel S & Fields RC et al.2019 Association of preoperative monocyte-to-lymphocyte and neutrophil-to-lymphocyte ratio with recurrence-free and overall survival after resection of pancreatic neuroendocrine tumors (US-NETSG). Journal of Surgical Oncology 120 632638. (https://doi.org/10.1002/jso.25629)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Pape UF, Berndt U, Muller-Nordhorn J, Bohmig M, Roll S, Koch M, Willich SN & Wiedenmann B 2008 Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocrine-Related Cancer 15 10831097. (https://doi.org/10.1677/ERC-08-0017)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Park JK, Paik WH, Lee K, Ryu JK, Lee SH & Kim YT 2017 DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors. Oncotarget 8 4979649806. (https://doi.org/10.18632/oncotarget.17964)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Patel SP, Othus M, Chae YK, Giles FJ, Hansel DE, Singh PP, Fontaine A, Shah MH, Kasi A & Baghdadi TA et al.2020 A Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors. Clinical Cancer Research 26 22902296. (https://doi.org/10.1158/1078-0432.CCR-19-3356)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Pavel M, Jann H, Prasad V, Drozdov I, Modlin IM & Kidd M 2017 NET blood transcript analysis defines the crossing of the clinical Rubicon: when stable disease becomes progressive. Neuroendocrinology 104 170182. (https://doi.org/10.1159/000446025)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Primavesi F, Andreasi V, Hoogwater FJH, Partelli S, Wiese D, Heidsma C, Cardini B, Klieser E, Marsoner K & Fröschl U et al.2020 A preoperative clinical risk score including C-reactive protein predicts histological tumor characteristics and patient survival after surgery for sporadic non-functional pancreatic neuroendocrine neoplasms: an international multicenter cohort study. Cancers 12 1235. (https://doi.org/10.3390/cancers12051235)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Roy S, Laframboise WA, Liu TC, Cao D, Luvison A, Miller C, Lyons MA, O’Sullivan RJ, Zureikat AH & Hogg ME et al.2018 Loss of chromatin-remodeling proteins and/or CDKN2A associates with metastasis of pancreatic neuroendocrine tumors and reduced patient survival times. Gastroenterology 154 2060 .e82063.e8. (https://doi.org/10.1053/j.gastro.2018.02.026)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Salem ME, Puccini A, Grothey A, Raghavan D, Goldberg RM, Xiu J, Korn WM, Weinberg BA, Hwang JJ & Shields AF et al.2018 Landscape of tumor mutation load, mismatch repair deficiency, and PD-L1 expression in a large patient cohort of gastrointestinal cancers. Molecular Cancer Research 16 805812. (https://doi.org/10.1158/1541-7786.MCR-17-0735)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, Lawlor RT, Johns AL, Miller DK & Mafficini A et al.2017 Whole-genome landscape of pancreatic neuroendocrine tumours. Nature 543 6571. (https://doi.org/10.1038/nature21063)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Schmitt AM, Anlauf M, Rousson V, Schmid S, Kofler A, Riniker F, Bauersfeld J, Barghorn A, Probst-Hensch NM & Moch H et al.2007 WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. American Journal of Surgical Pathology 31 16771682. (https://doi.org/10.1097/PAS.0b013e31805f675d)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Shevach EM 2018 Foxp3(+) T regulatory cells: still many unanswered questions-A perspective after 20 years of study. Frontiers in Immunology 9 10481048. (https://doi.org/10.3389/fimmu.2018.01048)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Singhi AD, Liu TC, Roncaioli JL, Cao D, Zeh HJ, Zureikat AH, Tsung A, Marsh JW, Lee KK & Hogg ME et al.2017 Alternative lengthening of telomeres and loss of DAXX/ATRX expression predicts metastatic disease and poor survival in patients with pancreatic neuroendocrine tumors. Clinical Cancer Research 23 600609. (https://doi.org/10.1158/1078-0432.CCR-16-1113)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Sonbol MB, Mazza GL, Starr JS, Hobday TJ & Halfdanarson TR 2020 Incidence and survival patterns of pancreatic neuroendocrine tumors over the last two decades: a SEER database analysis. Journal of Clinical Oncology 38 629629. (https://doi.org/10.1200/JCO.2020.38.4_suppl.629)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Song YL, Yu R, Qiao XW, Bai CM, Lu CM, Xiao Y, Zhong DR, Chen J, Zhao YP & Zhang TP et al.2017 Prognostic relevance of UCH-L1 and alpha-internexin in pancreatic neuroendocrine tumors. Scientific Reports 7 2205. (https://doi.org/10.1038/s41598-017-02051-1)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Stefanoli M, La Rosa S, Sahnane N, Romualdi C, Pastorino R, Marando A, Capella C, Sessa F & Furlan D 2014 Prognostic relevance of aberrant DNA methylation in g1 and g2 pancreatic neuroendocrine tumors. Neuroendocrinology 100 2634. (https://doi.org/10.1159/000365449)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J & Kvols L 2011 First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117 268275. (https://doi.org/10.1002/cncr.25425)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH & Jacene H et al.2017 Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. New England Journal of Medicine 376 125135. (https://doi.org/10.1056/NEJMoa1607427)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • van Treijen MJC, Korse CM, van Leeuwaarde RS, Saveur LJ, Vriens MR, Verbeek WHM, Tesselaar MET & Valk GD 2018 Blood transcript profiling for the detection of neuroendocrine tumors: results of a large independent validation study. Frontiers in Endocrinology 9 740. (https://doi.org/10.3389/fendo.2018.00740)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • van Treijen MJC, van der Zee D, Heeres BC, Staal FCR, Vriens MR, Saveur LJ, Verbeek WHM, Korse CM, Maas M & Valk GD et al.2020 Blood molecular genomic analysis predicts the disease course of GEP NET patients: a validation study of the predictive value of the NETest®. Neuroendocrinology 111 586598. (https://doi.org/10.1159/000509091)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Vashist YK, Uzunoglu G, Deutsch L, Kalinin V, Zehler O, Alzadjali A, Kutup A, Izbicki JR & Yekebas EF 2011 Heme oxygenase-1 promoter polymorphism is a predictor of disease relapse in pancreatic neuroendocrine tumors. Journal of Surgical Research 166 e121e127. (https://doi.org/10.1016/j.jss.2010.11.898)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Viudez A, Carvalho FL, Maleki Z, Zahurak M, Laheru D, Stark A, Azad NS, Wolfgang CL, Baylin S & Herman JG et al.2016 A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET). Oncotarget 7 2495024961. (https://doi.org/10.18632/oncotarget.7436)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Wiese D, Kampe K, Waldmann J, Heverhagen AE, Bartsch DK & Fendrich V 2016 C-reactive protein as a new prognostic factor for survival in patients with pancreatic neuroendocrine neoplasia. Journal of Clinical Endocrinology and Metabolism 101 937944. (https://doi.org/10.1210/jc.2015-3114)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Wong LH 2010 Epigenetic regulation of telomere chromatin integrity in pluripotent embryonic stem cells. Epigenomics 2 639655. (https://doi.org/10.2217/epi.10.49)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Wong LH, McGhie JD, Sim M, Anderson MA, Ahn S, Hannan RD, George AJ, Morgan KA, Mann JR & Choo KH 2010 ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells. Genome Research 20 351360. (https://doi.org/10.1101/gr.101477.109)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Xu SS, Xu HX, Wang WQ, Li S, Li H, Li TJ, Zhang WH, Liu L & Yu XJ 2019 Tumor-infiltrating platelets predict postoperative recurrence and survival in resectable pancreatic neuroendocrine tumor. World Journal of Gastroenterology 25 62486257. (https://doi.org/10.3748/wjg.v25.i41.6248)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Yang QC, Wang YH, Lin Y, Xue L, Chen YJ, Chen MH & Chen J 2014 Expression of O(6)-methylguanine DNA methyltransferase (MGMT) and its clinical significance in gastroenteropancreatic neuroendocrine neoplasm. International Journal of Clinical and Experimental Pathology 7 42044212.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St Peter J, Cherfi A & Öberg KE 2011 Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. Journal of Clinical Endocrinology and Metabolism 96 37413749. (https://doi.org/10.1210/jc.2011-0666)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H & Voi M et al.2016 Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387 968977. (https://doi.org/10.1016/S0140-6736(1500817-X)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Zandee WT, van Adrichem RC, Kamp K, Feelders RA, van Velthuysen MF & de Herder WW 2017 Incidence and prognostic value of serotonin secretion in pancreatic neuroendocrine tumours. Clinical Endocrinology 87 165170. (https://doi.org/10.1111/cen.13364)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Zhang WH, Wang WQ, Gao HL, Xu SS, Li S, Li TJ, Han X, Xu HX, Li H & Jiang W et al.2020a Tumor-infiltrating neutrophils predict poor survival of non-functional pancreatic neuroendocrine tumor. Journal of Clinical Endocrinology and Metabolism 105 dgaa196. (https://doi.org/10.1210/clinem/dgaa196)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Zhang WH, Wang WQ, Han X, Gao HL, Xu SS, Li S, Li TJ, Xu HX, Li H & Ye LY et al.2020b Infiltrating pattern and prognostic value of tertiary lymphoid structures in resected non-functional pancreatic neuroendocrine tumors. Journal for ImmunoTherapy of Cancer 8 e001188. (https://doi.org/10.1136/jitc-2020-001188)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Zhou B, Zhan C, Wu J, Liu J, Zhou J & Zheng S 2017a Prognostic significance of preoperative neutrophil-to-lymphocyte ratio in surgically resectable pancreatic neuroendocrine tumors. Medical Science Monitor 23 55745588. (https://doi.org/10.12659/msm.907182)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Zhou B, Zhan C, Wu J, Liu J, Zhou J & Zheng S 2017b Prognostic significance of preoperative gamma-glutamyltransferase to lymphocyte ratio index in nonfunctional pancreatic neuroendocrine tumors after curative resection. Scientific Reports 7 13372. (https://doi.org/10.1038/s41598-017-13847-6)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Zhou B, Xiang J, Zhan C, Liu J & Yan S 2019 STK33 promotes the growth and progression of human pancreatic neuroendocrine tumour via activation of the PI3K/AKT/mTOR pathway. Neuroendocrinology 110 307320. (https://doi.org/10.1159/000501829)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Zhou W, Kuang T, Han X, Chen W, Xu X, Lou W & Wang D 2020 Prognostic role of lymphocyte-to-monocyte ratio in pancreatic neuroendocrine neoplasms. Endocrine Connections 9 289298. (https://doi.org/10.1530/EC-19-0541)

    • PubMed
    • Search Google Scholar
    • Export Citation